Board of Directors

Naseem Amin serves as the Chairman of the Board of Directors. Dr. Amin has broad industry experience in the biotech and medical device industries and has served as the Chief Executive Officer at Orphalan since June 2017. He was the Chairman of Arix Bioscience plc, a global venture capital company focused on investing in life sciences, until April 2021. Dr. Amin served as a Venture Partner at Advent Life Sciences until 2020 and as the Chief Scientific Officer of Smith and Nephew Plc until 2014. Previously, he was Senior Vice President, Business Development, at Biogen Idec from 2005 to 2009, and was with Genzyme Corporation from 1999 to 2005, most recently as Head, International Business Development, and where he has also led the clinical development of five currently marketed therapeutic products. Dr. Amin began his career at Baxter Healthcare Corporation, where he served as Director, Medical Marketing and Portfolio Strategy, Renal Division. He currently serves as an Advisory Board member for Imperial College, Department of Biomedical Engineering, and as Chairman of OPEN-London, a non-profit organization focused on encouraging and mentoring South Asians from Pakistan who are interested in starting entrepreneurial companies. Dr. Amin received his medical degree from the Royal Free School of Medicine, London, and an MBA from the Kellogg Graduate School of Management, Northwestern University.

_{Independent Director}

Scott Bruder currently leads Bruder Consulting International with a global team that provides scientific, clinical, regulatory and development strategy services to medical device, regenerative medicine and biotechnology companies, investment banks, venture partners and private equity firms. He is also an adjunct Professor of Biomedical Engineering at Case Western Reserve University, where he previously served as an adjunct faculty member in the Department of Orthopaedic Surgery for thirteen years. Dr Bruder currently serves as the Chairman of the Board of Directors of Amendia, a privately held, leading provider of innovative medical devices used during spinal surgery procedures. Dr Bruder served as the Chief Medical and Scientific Officer of Stryker Corporation from 2012 until 2014, and was the Chief Scientific and Technology Officer for Becton, Dickinson and Company from 2007 until 2012. Previously, Dr. Bruder held a number of senior executive and scientific roles at Johnson & Johnson, Anika Therapeutics and Osiris Therapeutics. Dr. Bruder is a magna cum laude graduate from Brown University with a Sc.B. in Biology, and a graduate of Case Western Reserve University School of Medicine, where he simultaneously earned an M.D. and a Ph.D. in stem cell biology.

_{Independent Director}

Mary Ann Cloyd was a Senior Partner with PricewaterhouseCoopers (PwC) with responsibility for leading PwC’s Center for Board Governance at the time of her retirement in 2015. Ms. Cloyd has over 39 years of public accounting experience serving multinational corporate clients in a variety of industries including biotechnology and pharmaceuticals. Ms. Cloyd has served on both PwC’s Global and US Boards, where she chaired the Risk Management, Ethics & Compliance Committee and the Partner Admissions Committee on the US Board. On the Global Board, she served on the Risk and Operations Committee and the Clients Committee. Ms. Cloyd is on the Board of Trustees of the PricewaterhouseCoopers Charitable Foundation, Inc. and a past President of the Foundation, and she is Chair of the UCLA Iris Cantor Women’s Center Advisory Board. Ms. Cloyd graduated Summa Cum Laude from Baylor University with a Bachelor of Business Administration.

_{Independent Director}